Followers | 4054 |
Posts | 151766 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
![](https://investorshub.advfn.com/uicon/162645.png?cb=1681428050)
Friday, November 05, 2021 12:17:12 PM
this chit has to be illegal
its freakin sad that they can manipulate, wash trade, naked short the hell out of anything they want, not much we can do about it, ecxcept shake our heads and try to make some money off the BS
Recent ALZN News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/11/2024 08:30:19 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/03/2024 08:30:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/31/2024 08:59:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:30:23 PM
- Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel • Business Wire • 05/22/2024 12:00:00 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:30:15 PM
- Alzamend Neuro Announces Initial Closing of Private Placement • Business Wire • 05/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:30:25 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/10/2024 09:06:26 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/10/2024 08:30:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 10:30:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:20:24 PM
- Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million • Business Wire • 05/09/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/07/2024 08:31:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:30:33 PM
- Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program • Business Wire • 05/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:30:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 09:30:30 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients • Business Wire • 12/11/2023 01:00:00 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients • Business Wire • 11/20/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:30:19 PM
- Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement • Business Wire • 11/16/2023 01:00:00 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM